Molecular Targeted Therapy for Alzheimer’s Disease

Editors: Swarupananda Mukherjee, Souvik Roy, Dipanjan Karati

Molecular Targeted Therapy for Alzheimer’s Disease

ISBN: 979-8-89881-565-3
eISBN: 979-8-89881-564-6 (Online)

Introduction

Molecular Targeted Therapy for Alzheimer’s Disease is a comprehensive exploration of the molecular mechanisms, pathological pathways, and emerging therapeutic strategies associated with Alzheimer’s disease (AD). Positioned at the intersection of neuroscience, molecular biology, pharmacology, and biotechnology, the book focuses on targeted therapeutic approaches aimed at understanding and managing one of the world’s most complex neurodegenerative disorders.

The book systematically examines major molecular contributors to Alzheimer’s disease, including glutamate and NMDA receptor signalling, tau protein dysfunction, Axl kinase activity, NFAT dysregulation, oxidative stress, neuroinflammation, and microRNA-mediated pathways. It further explores innovative treatment strategies such as nanotechnology-based drug delivery systems, anti-amyloid antibody therapies, immunotherapy, small-molecule therapeutics, natural product-based interventions, and biopolymer-assisted treatment approaches. The concluding chapters discuss integrative molecular and targeted therapeutic frameworks that bridge current discoveries with future innovations in Alzheimer’s disease management.


Key Features

  • - Comprehensive coverage of molecular mechanisms underlying Alzheimer’s disease.
  • - Detailed discussions of targeted therapeutic and immunotherapeutic strategies.
  • - Insights into nanotechnology, small molecules, biopolymers, and natural-product-based treatments.
  • - Integration of molecular biology, pharmacology, and computational approaches focuses on emerging innovations and future directions in Alzheimer’s disease therapy.

Target Readership :

Researchers, neuroscientists, pharmacologists, clinicians, postgraduate students, and academics in neuroscience, molecular medicine, biotechnology, pharmacology, and neurodegenerative disease research.

Foreword

Alzheimer’s disease continues to challenge scientists, clinicians, and caregivers alike as one of the most complex and devastating neurodegenerative disorders of our time. Despite decades of research, effective long-term treatments remain elusive. However, recent advances in molecular biology, pharmacology, and neuroimmunology have begun to reshape our understanding of the disease's underlying mechanisms, offering hope for new and more effective therapeutic strategies.

This timely and compelling book, "Molecular Targeted Therapy for Alzheimer’s Disease," provides a comprehensive and forward-looking exploration into the evolving landscape of Alzheimer’s research. It brings together emerging perspectives on the pathophysiology of the disease, highlighting innovative molecular targets, cutting-edge drug development, and integrative therapeutic approaches that extend beyond the traditional amyloid- and tau-focused paradigms.

The chapters, authored by experts in the field, offer readers a deep dive into critical areas such as neuroinflammation, mitochondrial dysfunction, axl kinase disregulation, tau protein hyperphosphorylation, miRNA, and biopolymer-based therapeutic approaches. This book not only elucidates the science behind these developments but also discusses the translational challenges and future directions necessary to bridge laboratory findings with clinical practice.

Whether you are a researcher, clinician, student, or stakeholder in neurodegenerative disease care and policy, this book serves as an invaluable resource. It encourages a multidisciplinary approach and fosters a renewed sense of urgency and innovation in tackling one of the most pressing public health concerns of the 21st century.

In a field that is rapidly evolving, "Molecular Targeted Therapy for Alzheimer’s Disease" stands as a testament to the resilience and ingenuity of the scientific community. It is with great admiration and hope that I commend this work to all readers who are committed to making a difference in the battle against Alzheimer’s disease.

Debasis Bagchi
Department of Pharmaceutical Sciences
Texas Southern University
Houston, Texas, USA